Related Experiment Video
Updated: Aug 7, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
[Constraints on publication rights in industry-initiated clinical trials--secondary publication]
Peter C Gøtzsche1, Asbjørn Hróbjartsson, Helle Krogh Johansen
1H:S Rigshospitalet, Det Nordiske Cochrane Center, DK-2100 København Ø. pcg@cochrane.dk
Abstract:
In 22 of 44 industry-initiated clinical trial protocols from 1994-95, it was noted that the sponsor either owned the data or needed to approve the manuscript; another 18 protocols had other constraints. Furthermore, in 16 trials, the sponsor had access to accumulating data, and in an additional 16 trials the sponsor could stop the trial at any time, for any reason. These facts were not noted in any of the trial reports. We found similar constraints on publication rights in 44 protocols from 2004. This tight sponsor control over industry-initiated trials should be changed.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinically Relevant Drug Product Specifications: Methods of Establishment
Preclinical Development: Overview
Bioequivalence studies: Biowaivers